Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25761056 | 0.92 | S1PR1 (0.43) | S1PR1S1PR3S1PR5OPRL1S1PR4 | |
| SCHEMBL25758843 | 0.92 | S1PR1 (0.43) | S1PR1S1PR3S1PR5OPRL1S1PR4 | |
| SCHEMBL25757510 | 0.90 | S1PR1 (0.40) | S1PR1S1PR3S1PR5OPRL1S1PR4 | |
| SCHEMBL25247165 | 0.90 | S1PR1 (0.40) | S1PR1S1PR3S1PR5OPRL1S1PR4 | |
| SCHEMBL25246953 | 0.90 | S1PR1 (0.40) | S1PR1S1PR3S1PR5OPRL1S1PR4 | |
| SCHEMBL25758910 | 0.89 | S1PR1 (0.41) | S1PR1S1PR3S1PR5OPRL1S1PR4 | |
| SCHEMBL25759767 | 0.89 | S1PR1 (0.41) | S1PR1S1PR3S1PR5OPRL1S1PR4 | |
| SCHEMBL25759671 | 0.89 | S1PR1 (0.41) | S1PR1S1PR3S1PR5OPRL1S1PR4 | |
| SCHEMBL25757501 | 0.88 | S1PR1 (0.38) | S1PR1S1PR3S1PR5OPRL1S1PR4 | |
| SCHEMBL25758803 | 0.87 | S1PR1 (0.43) | S1PR1S1PR3S1PR5OPRL1S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202977-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | RENAGADE THERAPEUTICS MANAGEMENT INC. | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202977-A1 | CYCLIC LIPIDS AND METHODS OF USE THEREOF | SGMS1, SGMS2, LNPEP | CPB2 476/4885S1PR1 817/4885S1PR3 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.